Cat. #161579
MB49-luc Cell Line
Cat. #: 161579
Availability: 8-10 weeks
Organism: Mouse
Tissue: Bladder
Disease: Cancer
Model: Tumourigenic line
£1,110.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Jeffrey Schlom, PhD
Institute: National Cancer Institute
Primary Citation: Vandeveer et al. Cancer Immunol Res. 2016 May, 4(5):452-62. PMID: 26921031
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MB49-luc Cell Line
- Alternate name: MB49-luciferase, MB49-luc, MB-49-Luc, MB49luc, MB-49-luc, MB49-LUC, MB49 Luciferase (firefly) Cells
- Cancer: Genitourinary cancer
- Cancers detailed: Bladder
- Research fields: Cancer
- Parental cell: MB49 Cell Line
- Organism: Mouse
- Gender: Male
- Tissue: Bladder
- Disease: Cancer
- Morphology: Epithelial cells
- Growth properties: Adherent
- Model: Tumourigenic line
- Crispr: No
- Conditional: No
- Description: MB49-luc is an aggressive, bioluminescent orthotopic bladder cancer model stably expressing luciferase, derived from the well-established MB49 cell line. The bioluminescence can be detected by in vivo imaging and offers a readout for tumour take, growth and reduction. Similarly to its parental cell line MB49 (Cat. #: 153368), it forms tumours when injected subcutaneously or orthotopically into mouse bladders. Specifically, the orthotopic intravesical bladder tumour model based on MB49-luc offers a system to study immune-related factors involved in non-muscle invasive, non-metastatic bladder tumour growth, including anti-tumour effects of treatments such as immune checkpoint inhibitors. It also provides a bladder cancer model to study mechanisms of immunotherapy non-responders, to help identifying effective immune-based combination therapies and PD-L1 function within a tumour microenvironment devoid of T cells.
- Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
- Production details: Parental MB49 cells transfected with a pSELECT-zeo-LucSh plasmid using Lipofectamine (InvivoGen) for luciferase expression detected by in vivo imaging
- Biosafety level: 1
Target Details
- Target: PD-1, the programmed death-1 receptor
- Target background: The programmed death-1 (PD-1) receptor is a checkpoint inhibitor, that interacts with distinct ligands, PD-L1 (B7-H1, CD274). PD-L1 is expressed on a wide variety of human and mouse tumour cells and some immune cell populations
Applications
- Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
- Application notes: Identification host antitumor immune mechanisms and evaluation combinations of immune-based therapies for carcinoma in situ and non–muscle invasive, non-metastatic urothelial carcinoma
Handling
- Growth medium: Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated foetal bovine serum supplemented with 1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, and penicillin/streptomycin (100 U/mL).
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
Related Tools
- Related tools: MB49 Cell Line
References
- Domingos-Pereira et al. Int J Mol Sci. 2022. 24(1):123. PMID: 36613562.
- Vandeveer et al. Cancer Immunol Res. 2016. 4(5):452-462. PMID: 26921031.
